GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (AMEX:TOVX) » Definitions » Cyclically Adjusted FCF per Share

TOVX (Theriva Biologics) Cyclically Adjusted FCF per Share : $-1,265.93 (As of Dec. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Theriva Biologics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Theriva Biologics's adjusted free cash flow per share for the three months ended in Dec. 2024 was $-1.686. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1,265.93 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 10.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 6.20% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 5.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Theriva Biologics was 29.00% per year. The lowest was -1.50% per year. And the median was 8.80% per year.

As of today (2025-04-30), Theriva Biologics's current stock price is $1.35. Theriva Biologics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was $-1,265.93. Theriva Biologics's Cyclically Adjusted Price-to-FCF of today is .


Theriva Biologics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Theriva Biologics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics Cyclically Adjusted FCF per Share Chart

Theriva Biologics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,764.29 -1,780.45 -1,641.54 -1,516.09 -1,265.93

Theriva Biologics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,516.09 -1,478.82 -1,425.62 -1,344.84 -1,265.93

Competitive Comparison of Theriva Biologics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Theriva Biologics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Theriva Biologics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Theriva Biologics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-1.686/133.1571*133.1571
=-1.686

Current CPI (Dec. 2024) = 133.1571.

Theriva Biologics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -684.500 99.621 -914.927
201506 -911.625 100.684 -1,205.648
201509 -1,560.800 100.392 -2,070.211
201512 -1,101.400 99.792 -1,469.643
201603 -571.800 100.470 -757.827
201606 -532.818 101.688 -697.707
201609 -613.700 101.861 -802.255
201612 -827.231 101.863 -1,081.374
201703 -463.000 102.862 -599.362
201706 -410.000 103.349 -528.252
201709 -314.800 104.136 -402.531
201712 -262.333 104.011 -335.844
201803 -405.267 105.290 -512.531
201806 -287.200 106.317 -359.705
201809 -225.125 106.507 -281.456
201812 -53.065 105.998 -66.662
201903 -67.048 107.251 -83.244
201906 -45.182 108.070 -55.671
201909 -45.701 108.329 -56.175
201912 -53.806 108.420 -66.082
202003 -72.941 108.902 -89.187
202006 -27.378 108.767 -33.517
202009 -26.282 109.815 -31.868
202012 -36.847 109.897 -44.646
202103 -9.207 111.754 -10.970
202106 -4.917 114.631 -5.712
202109 -4.083 115.734 -4.698
202112 -9.093 117.630 -10.293
202203 -8.864 121.301 -9.730
202206 -6.871 125.017 -7.318
202209 -7.028 125.227 -7.473
202212 -8.507 125.222 -9.046
202303 -9.286 127.348 -9.710
202306 -6.427 128.729 -6.648
202309 -4.519 129.860 -4.634
202312 -9.659 129.419 -9.938
202403 -7.115 131.776 -7.190
202406 -4.448 132.554 -4.468
202409 -3.451 133.029 -3.454
202412 -1.686 133.157 -1.686

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Theriva Biologics  (AMEX:TOVX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Theriva Biologics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Theriva Biologics Business Description

Industry
Traded in Other Exchanges
N/A
Address
9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Executives
Steven A Shallcross director, officer: CEO and CFO C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Francis Tufaro officer: Chief Operating Officer 9605 MEDICAL CENTER DRIVE SUITE 270, ROCKVILLE MD 20850
John J Monahan director
Scott Tarriff director 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Joseph A. Sliman officer: CHIEF MEDICAL OFFICER 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE MD 20850
Jeffrey Scott Riley director C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Intrexon Corp 10 percent owner 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Charles Evan Ballantyne officer: CHIEF FINANCIAL OFFICER 27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Nelson K. Stacks director C/O ADEONA PHARMACEUTICALS, INC., 3985 RESEARCH PARK DRIVE, SUITE 200, ANN ARBOR MI 48108
Lyon Lyman Max Jr director, officer: CEO & President C/O ADEONA PHARMACEUTICALS, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
David A. Newsome officer: Chief Scientific Officer 3930 VARSITY DRIVE, C/O PIPEX PHARMACEUTICALS, INC., ANN ARBOR MI 48108
James S Kuo director 509 MADISON AVE 14TH FL, NEW YORK NY 10022
Daniel J Dorman director
Wayne George Holman 10 percent owner 430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022

Theriva Biologics Headlines